78 related articles for article (PubMed ID: 27103110)
1. Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use.
Wang C; Hong J; Yang Z; Zhou X; Yang Y; Kong Y; Chen B; Wu H; Qian BZ; Dimitrov DS; Zhou X; Wu Y; Ying T
Small Methods; 2022 Feb; 6(2):e2100966. PubMed ID: 35174992
[TBL] [Abstract][Full Text] [Related]
2. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires.
DeKosky BJ; Lungu OI; Park D; Johnson EL; Charab W; Chrysostomou C; Kuroda D; Ellington AD; Ippolito GC; Gray JJ; Georgiou G
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2636-45. PubMed ID: 27114511
[TBL] [Abstract][Full Text] [Related]
3. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.
Datta-Mannan A; Croy JE; Schirtzinger L; Torgerson S; Breyer M; Wroblewski VJ
MAbs; 2016 Jul; 8(5):969-82. PubMed ID: 27111637
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.
Barzaman K; Vafaei R; Samadi M; Kazemi MH; Hosseinzadeh A; Merikhian P; Moradi-Kalbolandi S; Eisavand MR; Dinvari H; Farahmand L
Cancer Cell Int; 2022 Aug; 22(1):259. PubMed ID: 35986321
[TBL] [Abstract][Full Text] [Related]
5. hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers.
Martinelli I; Modica C; Chiriaco C; Basilico C; Hughes JM; Corso S; Giordano S; Comoglio PM; Vigna E
J Exp Clin Cancer Res; 2022 Mar; 41(1):112. PubMed ID: 35351166
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.
Svilenov HL; Sacherl J; Protzer U; Zacharias M; Buchner J
Nat Commun; 2021 Nov; 12(1):6737. PubMed ID: 34795299
[TBL] [Abstract][Full Text] [Related]
7. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase.
Fernandes M; Duplaquet L; Tulasne D
BMB Rep; 2019 Apr; 52(4):239-249. PubMed ID: 30670153
[TBL] [Abstract][Full Text] [Related]
9. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
Frazier NM; Brand T; Gordan JD; Grandis J; Jura N
Oncogene; 2019 Mar; 38(11):1936-1950. PubMed ID: 30390071
[TBL] [Abstract][Full Text] [Related]
10. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
11. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
Pan H; Liu J; Deng W; Xing J; Li Q; Wang Z
Int J Nanomedicine; 2018; 13():3189-3201. PubMed ID: 29881272
[TBL] [Abstract][Full Text] [Related]
12. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.
Vigna E; Pacchiana G; Chiriaco C; Cignetto S; Fontani L; Michieli P; Comoglio PM
J Mol Med (Berl); 2014 Jan; 92(1):65-76. PubMed ID: 24013625
[TBL] [Abstract][Full Text] [Related]
15. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.
Pacchiana G; Chiriaco C; Stella MC; Petronzelli F; De Santis R; Galluzzo M; Carminati P; Comoglio PM; Michieli P; Vigna E
J Biol Chem; 2010 Nov; 285(46):36149-57. PubMed ID: 20833723
[TBL] [Abstract][Full Text] [Related]
16. Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.
Cignetto S; Modica C; Chiriaco C; Fontani L; Milla P; Michieli P; Comoglio PM; Vigna E
Mol Oncol; 2016 Jun; 10(6):938-48. PubMed ID: 27103110
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
Vigna E; Chiriaco C; Cignetto S; Fontani L; Basilico C; Petronzelli F; Comoglio PM
Mol Oncol; 2015 Nov; 9(9):1760-72. PubMed ID: 26119717
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
